Alpine Global Management’s Cabaletta Bio CABA Stock Holding History

Alpine Global Management’s Portfolio CABA Stock Details CABA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-10,984	Closed	-$42K	–	483
2021 Q4	$42K	Buy	+10,984	New	+$117K	0.01%	710
2021 Q3	–	Sell	-14,072	Closed	-$121K	–	308
2021 Q2	$121K	Buy	+14,072	New	+$138K	0.02%	258

Other funds holding CABA

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Alpine Global Management's CABA Position: Q1 2022 in Review

Alpine Global Management sold out of Cabaletta Bio (CABA) in Q1 2022, closing a stake of 10,984 shares — an estimated $42K sold.

Alpine Global Management first reported a position in CABA in Q2 2021 and held it in 2 quarters. The position peaked at $121K in Q2 2021. 62 funds tracked by Wall St. Rank hold CABA as of Q1 2022.

Alpine Global Management reported no remaining Cabaletta Bio position as of Q1 2022 after selling out during the quarter.
Alpine Global Management sold 10,984 Cabaletta Bio shares in Q1 2022, an estimated $42K.
Alpine Global Management first reported a position in Cabaletta Bio in Q2 2021 and held it in 2 quarters.
Alpine Global Management's Cabaletta Bio position peaked at $121K in Q2 2021.
62 funds tracked by Wall St. Rank held Cabaletta Bio as of Q1 2022.

Based on Alpine Global Management's 13F filing for Q1 2022, filed 13 May 2022.